Targeted cancer therapies in the twenty-first century: lessons from imatinib (Q37710963)

22 August 2017

1 reference

title

Targeted cancer therapies in the twenty-first century: lessons from imatinib (English)

1 reference

22 August 2017

F Stegmeier

1 reference

22 August 2017

M Warmuth

series ordinal

1 reference

22 August 2017

W R Sellers

series ordinal

1 reference

22 August 2017

M Dorsch

series ordinal

1 reference

22 August 2017

language of work or name

English

0 references

publication date

17 March 2010

1 reference

Clinical Pharmacology & Therapeutics

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

543-552

1 reference

Translating insights from the cancer genome into clinical practice

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Reversible tumorigenesis by MYC in hematopoietic lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Translation of the Philadelphia chromosome into therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Gastrointestinal stromal tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Molecularly targeted therapy for melanoma: current reality and future options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

inferred from DOI database lookup

7 January 2021

based on heuristic

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.297

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2009.297

1 reference

22 August 2017

1 reference